跳转至内容
Merck

SML2282

Sigma-Aldrich

依维莫司

≥95% (HPLC), powder, P-glycoprotein substrate

别名:

依维莫司, 40-O-(2-羟乙基)雷帕霉素, 42-O-(2-羟乙基)雷帕霉素, RAD 001, RAD001, SDZ-RAD, 42-O-(2-羟乙基)雷帕霉素

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C53H83NO14
分子量:
958.22
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

product name

依维莫司, ≥95% (HPLC)

化驗

≥95% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

O=C(C([C@@]1(O)[C@H](C)CC[C@](C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C2=O)([H])O1)=O)N3[C@H](C(O[C@@]([C@@H](C[C@@]4([H])C[C@@H](OC)[C@H](OCCO)CC4)C)([H])CC([C@H](C)/C=C(C)/[C@@H](O)[C@H]2OC)=O)=O)CCCC3

InChI

1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

InChI 密鑰

HKVAMNSJSFKALM-GKUWKFKPSA-N

基因資訊

human ... FKBP1A(2280)

正在寻找类似产品? 访问 产品对比指南

應用

依维莫司已被用作雷帕霉素复合物1(mTORC1)抑制剂的机制靶标,以研究其对MCF7和MDA-MB-231细胞系的作用。

生化/生理作用

依维莫司,P-糖蛋白(P-gp)的底物,可用于治疗晚期神经内分泌肿瘤(NETs)。
依维莫司,雷帕霉素(西罗莫司)的40-O-(2-羟乙基)衍生物,是雷帕霉素(mTOR)机制靶标的有效和选择性抑制剂。依维莫司对mTORC1蛋白复合物具有选择性。依维莫司表现出有效的免疫抑制和抗癌活性。

象形圖

Health hazardEnvironment

訊號詞

Warning

危險分類

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Repr. 2 - STOT RE 2

標靶器官

Kidney,Testes

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Barkovskaya A, et al.
Scientific Reports, 9(1), 5670-5670 (2019)
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence
Lee L, et al.
Expert Opinion on Pharmacotherapy, 19(8), 909-928 (2018)
Chemical modification of rapamycin: the discovery of SDZ RAD.
R Sedrani et al.
Transplantation proceedings, 30(5), 2192-2194 (1998-09-02)
Gerke Ariaans et al.
BMC cancer, 17(1), 232-232 (2017-03-31)
Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract everolimus-induced hyperglycemia, as well as enhancing anti-cancer efficacy. We investigated the glucose-dependent
Heidi A Lane et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(5), 1612-1622 (2009-02-19)
Comparison of the antiangiogenic/vascular properties of the oral mammalian target of rapamycin (mTOR) inhibitor RAD001 (everolimus) and the vascular endothelial growth factor receptor (VEGFR) inhibitor vatalanib (PTK/ZK). Antiproliferative activity against various tumor histotypes and downstream effects on the mTOR pathway

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门